EP3525809A4 - Verfahren und zusammensetzungen zur tusc2-immuntherapie - Google Patents

Verfahren und zusammensetzungen zur tusc2-immuntherapie Download PDF

Info

Publication number: EP3525809A4
Authority: EP; European Patent Office
Prior art keywords: tusc2; immunotherapy; compositions; methods; tusc2 immunotherapy
Prior art date: 2016-10-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP17861125.7A

Other languages

English (en)

French (fr)

Other versions

EP3525809A1 (de

EP3525809B1 (de

Inventor

Jack A. Roth

Lin Ji

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

The University of Texas System

The University of Texas at Austin

Original Assignee

The University of Texas System

The University of Texas at Austin

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-10-12

Filing date

2017-10-12

Publication date

2020-06-03

2017-10-12 Application filed by The University of Texas System, The University of Texas at Austin filed Critical The University of Texas System

2017-10-12 Priority to EP26157266.3A priority Critical patent/EP4755459A3/de

2019-08-21 Publication of EP3525809A1 publication Critical patent/EP3525809A1/de

2020-06-03 Publication of EP3525809A4 publication Critical patent/EP3525809A4/de

2026-03-11 Application granted granted Critical

2026-03-11 Publication of EP3525809B1 publication Critical patent/EP3525809B1/de

Status Active legal-status Critical Current

2037-10-12 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Mycology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Marine Sciences & Fisheries (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Toxicology (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

EP17861125.7A 2016-10-12 2017-10-12 Verfahren und zusammensetzungen zur tusc2-immuntherapie Active EP3525809B1 (de)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP26157266.3A EP4755459A3 (de)	2016-10-12	2017-10-12	Verfahren und zusammensetzungen für tusc2-immuntherapie

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662407329P	2016-10-12	2016-10-12
PCT/US2017/056338 WO2018071668A1 (en)	2016-10-12	2017-10-12	Methods and compositions for tusc2 immunotherapy

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
EP26157266.3A Division EP4755459A3 (de)	2016-10-12	2017-10-12	Verfahren und zusammensetzungen für tusc2-immuntherapie

Publications (3)

Publication Number	Publication Date
EP3525809A1 EP3525809A1 (de)	2019-08-21
EP3525809A4 true EP3525809A4 (de)	2020-06-03
EP3525809B1 EP3525809B1 (de)	2026-03-11

Family

ID=61906060

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP26157266.3A Pending EP4755459A3 (de)	2016-10-12	2017-10-12	Verfahren und zusammensetzungen für tusc2-immuntherapie
EP17861125.7A Active EP3525809B1 (de)	2016-10-12	2017-10-12	Verfahren und zusammensetzungen zur tusc2-immuntherapie

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP26157266.3A Pending EP4755459A3 (de)	2016-10-12	2017-10-12	Verfahren und zusammensetzungen für tusc2-immuntherapie

Country Status (15)

Country	Link
US (3)	US11278592B2 (de)
EP (2)	EP4755459A3 (de)
JP (4)	JP7041136B2 (de)
KR (1)	KR102661905B1 (de)
CN (2)	CN116672456A (de)
AU (2)	AU2017342364B2 (de)
BR (1)	BR112019007365A2 (de)
CA (1)	CA3040458A1 (de)
CL (1)	CL2019001002A1 (de)
IL (2)	IL265965B2 (de)
MA (1)	MA46542A (de)
MX (1)	MX386249B (de)
RU (1)	RU2755903C2 (de)
SG (1)	SG11201903283UA (de)
WO (1)	WO2018071668A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3138555T3 (da)	2014-04-30	2020-12-14	Fujifilm Corp	Liposomsammensætning og fremgangsmåde til fremstilling heraf
WO2018071668A1 (en) *	2016-10-12	2018-04-19	Board Of Regents, The University Of Texas System	Methods and compositions for tusc2 immunotherapy
FI3811949T3 (fi)	2018-06-20	2024-09-13	Fujifilm Corp	Liposomikoostumukseen kapseloitua gemsitabiinia ja immuunitarkistuspistesalpaajaa käsittävä yhdistelmälääke
CN116121194B (zh) *	2023-02-27	2023-10-24	山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院)	一种肺癌免疫治疗耐药细胞系及其制备方法和应用
CN116482368B (zh) *	2023-05-09	2025-09-26	扬州大学	一种靶向检测肿瘤来源细胞外囊泡中microRNA的生物传感器的制备方法
WO2025208148A1 (en) *	2024-03-29	2025-10-02	Genprex, Inc.	Maintenance therapy for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20150086541A1 (en) *	2013-09-21	2015-03-26	Carlos Estuardo Aguilar-Cordova	Methods of Cytotoxic Gene Therapy To Treat Tumors
US20150297631A1 (en) *	2011-03-02	2015-10-22	Board Of Regents, The University Of Texas System	Tusc2 therapies

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4162282A (en)	1976-04-22	1979-07-24	Coulter Electronics, Inc.	Method for producing uniform particles
US4310505A (en)	1979-11-08	1982-01-12	California Institute Of Technology	Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4533254A (en)	1981-04-17	1985-08-06	Biotechnology Development Corporation	Apparatus for forming emulsions
US5030453A (en)	1983-03-24	1991-07-09	The Liposome Company, Inc.	Stable plurilamellar vesicles
US4728575A (en)	1984-04-27	1988-03-01	Vestar, Inc.	Contrast agents for NMR imaging
US4921706A (en)	1984-11-20	1990-05-01	Massachusetts Institute Of Technology	Unilamellar lipid vesicles and method for their formation
US4797368A (en)	1985-03-15	1989-01-10	The United States Of America As Represented By The Department Of Health And Human Services	Adeno-associated virus as eukaryotic expression vector
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US4737323A (en)	1986-02-13	1988-04-12	Liposome Technology, Inc.	Liposome extrusion method
IL79559A0 (en)	1986-07-29	1986-10-31	Univ Ramot	Contrast agents for nmr medical imaging
US4728578A (en)	1986-08-13	1988-03-01	The Lubrizol Corporation	Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers
US5851795A (en)	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
US5397987A (en)	1993-03-03	1995-03-14	Rheometrics, Inc.	Method and apparatus for analyzing samples using nuclear magnetic resonance
JPH08506247A (ja)	1993-07-09	1996-07-09	アムジェンボールダーインコーポレイテッド	組換えｃｔｌａ４ポリペプチドおよびその製造方法
US5855911A (en)	1995-08-29	1999-01-05	Board Of Regents, The University Of Texas System	Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6013516A (en)	1995-10-06	2000-01-11	The Salk Institute For Biological Studies	Vector and method of use for nucleic acid delivery to non-dividing cells
US5844905A (en)	1996-07-09	1998-12-01	International Business Machines Corporation	Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
US6770291B2 (en)	1996-08-30	2004-08-03	The United States Of America As Represented By The Department Of Health And Human Services	Liposome complexes for increased systemic delivery
EP0955999B1 (de)	1996-08-19	2001-12-05	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Neue liposomkomplexe mit erhöhter systemischer verabreichung
WO1998022122A1 (en)	1996-11-21	1998-05-28	Promega Corporation	Alkyl peptide amides and applications
US5891467A (en)	1997-01-31	1999-04-06	Depotech Corporation	Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
EP0970128A1 (de)	1997-03-21	2000-01-12	Brigham And Women's Hospital	Immuntherapeutische ctla-4 bindungspeptide
US5994136A (en)	1997-12-12	1999-11-30	Cell Genesys, Inc.	Method and means for producing high titer, safe, recombinant lentivirus vectors
ES2706547T3 (es)	1998-12-23	2019-03-29	Pfizer	Anticuerpos monoclonales humanos para CTLA-4
US7605238B2 (en)	1999-08-24	2009-10-20	Medarex, Inc.	Human CTLA-4 antibodies and their uses
NZ517202A (en)	1999-08-24	2004-05-28	Medarex Inc	Human CTLA-4 antibodies and their uses
US6680068B2 (en)	2000-07-06	2004-01-20	The General Hospital Corporation	Drug delivery formulations and targeting
US20020164715A1 (en)	2000-07-10	2002-11-07	Lin Ji	Chromosome 3p21.3 genes are tumor suppressors
WO2002100435A1 (en)	2001-06-11	2002-12-19	Centre Hospitalier Universitaire De Montreal	Compositions and methods for enhancing nucleic acid transfer into cells
WO2003015757A1 (en)	2001-08-16	2003-02-27	The Trustees Of The University Of Pennsylvania	Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
EP1519714B1 (de)	2002-06-28	2010-10-20	Protiva Biotherapeutics Inc.	Verfahren und vorrichtung zur herstellung von liposomen
EP1658304A4 (de)	2002-09-28	2009-01-14	Massachusetts Inst Technology	Mittel zur behandlung von grippe
US20040208921A1 (en)	2003-01-14	2004-10-21	Ho Rodney J. Y.	Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
HRP20120845T1 (hr)	2003-07-02	2012-11-30	Innate Pharma	Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
HUE033129T2 (en)	2003-07-24	2017-11-28	Innate Pharma Sa	Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells
WO2006003179A2 (en)	2004-07-01	2006-01-12	Novo Nordisk A/S	Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
JP5295568B2 (ja)	2005-01-06	2013-09-18	ノヴォノルディスクアー／エス	Ｋｉｒ結合剤およびその使用方法
US20090196850A1 (en)	2005-01-06	2009-08-06	Novo Nordisk A/S	Anti-Kir Combination Treatments and Methods
US8658778B2 (en)	2005-03-09	2014-02-25	Board Of Regents, The University Of Texas System	hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes
JP2009501237A (ja)	2005-03-14	2009-01-15	ボードオブリージェンツオブザユニバーシティーオブテキサスシステム	生物活性ｆｕｓ１ペプチドおよびナノ粒子−ポリペプチド複合体
CN101389314A (zh) *	2005-03-14	2009-03-18	得克萨斯大学体系董事会	生物活性fus1肽和纳米颗粒-多肽复合物
EP3530736A3 (de)	2005-05-09	2019-11-06	ONO Pharmaceutical Co., Ltd.	Humane monoklonale antikörper für den programmierten tod 1 (pd-1) und verfahren zur behandlung von krebs mit pd-1-antikörpern allein oder in kombination mit anderen immunotherapeutika
EP1934260B1 (de)	2005-10-14	2017-05-17	Innate Pharma	Zusammensetzungen und methoden zur behandlung proliferierender krankheiten
US20110052570A1 (en)	2005-10-26	2011-03-03	Children's Medical Center Corporation	Method to prognose response to anti-egfr therapeutics
WO2007092944A2 (en) *	2006-02-08	2007-08-16	Introgen Therapeutics, Inc.	Compositions and methods involving gene therapy and proteasome modulation
RU2008148329A (ru)	2006-05-09	2010-06-20	Колгейт-Палмолив Компани (US)	Система ухода за ротовой полостью
AU2008204433B2 (en)	2007-01-11	2014-03-13	Novo Nordisk A/S	Anti-KIR antibodies, formulations, and uses thereof
EP1987839A1 (de)	2007-04-30	2008-11-05	I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale	Zytotoxischer monoklonaler Anti-LAG-3-Antikörper und seine Verwendung bei der Behandlung und Vorbeugung von Organtransplantatabstoßung und Autoimmunerkrankungen
PT2170959E (pt)	2007-06-18	2014-01-07	Merck Sharp & Dohme	Anticorpos para o receptor humano de morte programada pd-1
EP2044949A1 (de)	2007-10-05	2009-04-08	Immutep	Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
PT2242773T (pt)	2008-02-11	2017-09-15	Cure Tech Ltd	Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en)	2008-03-12	2012-05-01	Merck Sharp & Dohme Corp.	PD-1 binding proteins
WO2010014784A2 (en)	2008-08-01	2010-02-04	Bristol-Myers Squibb Company	Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
AR072999A1 (es)	2008-08-11	2010-10-06	Medarex Inc	Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010098788A2 (en)	2008-08-25	2010-09-02	Amplimmune, Inc.	Pd-i antagonists and methods for treating infectious disease
US8709411B2 (en)	2008-12-05	2014-04-29	Novo Nordisk A/S	Combination therapy to enhance NK cell mediated cytotoxicity
CA2769473A1 (en)	2009-07-31	2011-02-03	N.V. Organon	Fully human antibodies to btla
EP2473523A2 (de)	2009-08-31	2012-07-11	Amplimmune, Inc.	Verfahren und zusammensetzungen zur hemmung von transplantatabstossung
EP2504028A4 (de)	2009-11-24	2014-04-09	Amplimmune Inc	Simultane hemmung von pd-l1/pd-l2
EP3053932B1 (de)	2010-02-19	2020-07-22	Xencor, Inc.	Neuartige ctla4-ig-immunadhäsine
PH12012501751A1 (en)	2010-03-04	2012-11-12	Macrogenics Inc	Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CA2818684C (en)	2010-11-22	2023-02-21	Innate Pharma Sa	Nk cell modulating treatments and methods for treatment of hematological malignancies
US9067997B2 (en)	2011-05-25	2015-06-30	Innate Pharma Sa	Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
WO2013006490A2 (en)	2011-07-01	2013-01-10	Cellerant Therapeutics, Inc.	Antibodies that specifically bind to tim3
US9676854B2 (en)	2011-08-15	2017-06-13	Medimmune, Llc	Anti-B7-H4 antibodies and their uses
US9422351B2 (en)	2011-11-03	2016-08-23	The Trustees Of The University Of Pennsylvania	Isolated B7-H4 specific compositions and methods of use thereof
US20130247924A1 (en)	2012-03-23	2013-09-26	Mark Scatterday	Electronic cigarette having a flexible and soft configuration
US9731012B2 (en)	2012-03-30	2017-08-15	President And Fellows Of Harvard College	Laser-actuated therapeutic nanoparticles
JP2014022858A (ja)	2012-07-17	2014-02-03	Murata Mfg Co Ltd	電力増幅器
US9308236B2 (en)	2013-03-15	2016-04-12	Bristol-Myers Squibb Company	Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
AU2014276440A1 (en) *	2013-06-03	2015-11-05	Novartis Ag	Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor
US9243068B2 (en)	2013-06-25	2016-01-26	Vaccinex, Inc.	Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases
CN105682683A (zh)	2013-08-02	2016-06-15	阿杜罗生物科技控股有限公司	结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
SMT202300039T1 (it)	2013-09-13	2023-03-17	Beigene Switzerland Gmbh	Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
UA122479C2 (uk)	2014-01-24	2020-11-25	Дана-Фарбер Кенсер Інстітьют, Інк.	Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
WO2016049385A1 (en) *	2014-09-24	2016-03-31	Apellis Pharmaceuticals, Inc.	Methods and compositions for cancer treatment and treatment selection
WO2018071668A1 (en) *	2016-10-12	2018-04-19	Board Of Regents, The University Of Texas System	Methods and compositions for tusc2 immunotherapy

2017
- 2017-10-12 WO PCT/US2017/056338 patent/WO2018071668A1/en not_active Ceased
- 2017-10-12 US US16/341,134 patent/US11278592B2/en active Active
- 2017-10-12 EP EP26157266.3A patent/EP4755459A3/de active Pending
- 2017-10-12 MX MX2019004359A patent/MX386249B/es unknown
- 2017-10-12 SG SG11201903283UA patent/SG11201903283UA/en unknown
- 2017-10-12 CA CA3040458A patent/CA3040458A1/en active Pending
- 2017-10-12 CN CN202310535801.7A patent/CN116672456A/zh active Pending
- 2017-10-12 RU RU2019114031A patent/RU2755903C2/ru active
- 2017-10-12 CN CN201780076886.XA patent/CN110072540B/zh active Active
- 2017-10-12 EP EP17861125.7A patent/EP3525809B1/de active Active
- 2017-10-12 AU AU2017342364A patent/AU2017342364B2/en active Active
- 2017-10-12 JP JP2019519701A patent/JP7041136B2/ja active Active
- 2017-10-12 IL IL265965A patent/IL265965B2/en unknown
- 2017-10-12 MA MA046542A patent/MA46542A/fr unknown
- 2017-10-12 BR BR112019007365-5A patent/BR112019007365A2/pt unknown
- 2017-10-12 IL IL322445A patent/IL322445A/en unknown
- 2017-10-12 KR KR1020197013556A patent/KR102661905B1/ko active Active
2019
- 2019-04-12 CL CL2019001002A patent/CL2019001002A1/es unknown
2022
- 2022-02-17 US US17/674,800 patent/US12485159B2/en active Active
- 2022-03-10 JP JP2022037295A patent/JP7825465B2/ja active Active
2023
- 2023-03-15 AU AU2023201601A patent/AU2023201601B2/en active Active
2024
- 2024-02-22 JP JP2024025307A patent/JP2024057000A/ja active Pending
2025
- 2025-08-06 US US19/292,000 patent/US20260027180A1/en active Pending
2026
- 2026-01-29 JP JP2026012818A patent/JP2026086498A/ja active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20150297631A1 (en) *	2011-03-02	2015-10-22	Board Of Regents, The University Of Texas System	Tusc2 therapies
US20150086541A1 (en) *	2013-09-21	2015-03-26	Carlos Estuardo Aguilar-Cordova	Methods of Cytotoxic Gene Therapy To Treat Tumors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "NCT01455389: FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer", CLINICAL TRIALS.GOV, 16 February 2016 (2016-02-16), pages 1 - 6, XP055662768, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT01455389?V_11=View#StudyPageTop> [retrieved on 20200128] *
KAWASHIMA HIROYUKI ET AL: "Synergistic inhibition of EGFR tyrosine kinase activity and NSCLC cell growth by combination treatment with FUS1-nanoparticle and gefitinib", AMERICAN ASSOCIATION FOR CANCER RESEARCH. PROCEEDINGS OF THE ANNUAL MEETING; 96TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US; ANAHEIM, CA, USA, vol. 46, 1 April 2005 (2005-04-01), pages 637, XP008151337, ISSN: 0197-016X *
LU CHARLES ET AL: "Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans", PLOS ONE,, vol. 7, no. 4, 1 April 2012 (2012-04-01), pages e34833 - 1, XP008152962, ISSN: 1932-6203, [retrieved on 20120425], DOI: 10.1371/JOURNAL.PONE.0034833 *
See also references of WO2018071668A1 *
W.-G. DENG ET AL: "Synergistic Tumor Suppression by Coexpression of FUS1 and p53 Is Associated with Down-regulation of Murine Double Minute-2 and Activation of the Apoptotic Protease-Activating Factor 1-Dependent Apoptotic Pathway in Human Non-Small Cell Lung Cancer Cells", CANCER RESEARCH, vol. 67, no. 2, 15 January 2007 (2007-01-15), pages 709 - 717, XP055025526, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-3463 *

Also Published As

Publication number	Publication date
US20200038480A1 (en)	2020-02-06
WO2018071668A1 (en)	2018-04-19
CA3040458A1 (en)	2018-04-19
RU2019114031A3 (de)	2020-11-13
CL2019001002A1 (es)	2019-11-08
AU2023201601A1 (en)	2023-04-13
AU2017342364B2 (en)	2022-12-15
EP3525809A1 (de)	2019-08-21
AU2017342364A1 (en)	2019-05-23
KR20190067216A (ko)	2019-06-14
JP2019534268A (ja)	2019-11-28
EP4755459A3 (de)	2026-07-29
CN110072540A (zh)	2019-07-30
IL322445A (en)	2025-09-01
IL265965B2 (en)	2026-05-01
EP3525809B1 (de)	2026-03-11
MX386249B (es)	2025-03-18
RU2755903C2 (ru)	2021-09-22
JP2024057000A (ja)	2024-04-23
JP7825465B2 (ja)	2026-03-06
RU2019114031A (ru)	2020-11-13
MA46542A (fr)	2021-03-31
IL265965B1 (en)	2026-01-01
EP4755459A2 (de)	2026-06-10
US20260027180A1 (en)	2026-01-29
IL265965A (en)	2019-06-30
JP2022081616A (ja)	2022-05-31
KR102661905B1 (ko)	2024-04-29
AU2023201601B2 (en)	2026-02-05
BR112019007365A2 (pt)	2019-07-09
CN116672456A (zh)	2023-09-01
JP7041136B2 (ja)	2022-03-23
US12485159B2 (en)	2025-12-02
US20220168388A1 (en)	2022-06-02
CN110072540B (zh)	2023-06-02
SG11201903283UA (en)	2019-05-30
JP2026086498A (ja)	2026-05-26
US11278592B2 (en)	2022-03-22

Legal Events

Date	Code	Title	Description
2018-04-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2019-07-19	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2019-07-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-08-21	17P	Request for examination filed	Effective date: 20190507
2019-08-21	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-08-21	AX	Request for extension of the european patent	Extension state: BA ME
2020-06-03	A4	Supplementary search report drawn up and despatched	Effective date: 20200504
2020-06-03	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 14/47 20060101ALI20200424BHEP Ipc: A61P 35/00 20060101ALI20200424BHEP Ipc: C07K 16/28 20060101ALI20200424BHEP Ipc: A61K 48/00 20060101ALI20200424BHEP Ipc: A61K 39/395 20060101ALI20200424BHEP Ipc: A61K 38/17 20060101AFI20200424BHEP
2020-07-24	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40012448 Country of ref document: HK
2021-02-26	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-03-31	17Q	First examination report despatched	Effective date: 20210302
2025-04-03	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2025-04-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2025-05-07	INTG	Intention to grant announced	Effective date: 20250404
2025-08-04	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2025-08-04	GRAL	Information related to payment of fee for publishing/printing deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR3
2025-08-04	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2025-08-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2025-09-03	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2025-09-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2025-09-10	INTC	Intention to grant announced (deleted)
2025-09-10	P01	Opt-out of the competence of the unified patent court (upc) registered	Free format text: CASE NUMBER: UPC_APP_2615_3525809/2025 Effective date: 20250806
2025-10-08	INTG	Intention to grant announced	Effective date: 20250904
2025-12-19	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2025-12-19	GRAL	Information related to payment of fee for publishing/printing deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR3
2025-12-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2026-01-13	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2026-01-13	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2026-01-21	INTC	Intention to grant announced (deleted)
2026-02-06	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2026-02-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2026-02-11	INTG	Intention to grant announced	Effective date: 20260113
2026-03-11	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2026-03-11	REG	Reference to a national code	Ref country code: CH Ref legal event code: F10 Free format text: ST27 STATUS EVENT CODE: U-0-0-F10-F00 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20260311 Ref country code: GB Ref legal event code: FG4D
2026-04-02	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602017094293 Country of ref document: DE
2026-04-08	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2026-07-07	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260611
2026-07-10	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260612
2026-07-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20260522 Year of fee payment: 10
2026-07-10	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG9D
2026-07-11	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260311
2026-07-14	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260611
2026-07-15	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260311 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260311
2026-07-15	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20260311
2026-07-17	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260311
2026-07-23	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20260526 Year of fee payment: 10
2026-07-24	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260311
2026-07-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260311

Publication	Publication Date	Title
EP3493827A4 (de)	2020-02-26	Zusammensetzungen und verfahren für die immuntherapie
IL286103B (en)	2022-06-01	Crispr-cas-related methods, compositions and components for cancer immunotherapy
IL286025A (en)	2021-10-31	Nanoparticle preparations and immunotherapy methods
EP3471745A4 (de)	2020-01-22	Verfahren und zusammensetzungen zur reduzierung von oxidativem stress
IL265844A (en)	2019-06-30	Anti-lag-3 antibodies and preparations
IL261163B (en)	2022-10-01	Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
EP3405577A4 (de)	2019-09-11	Zusammensetzungen und verfahren zur hemmung des faktors d
IL262176A (en)	2018-11-29	Anti-tim-3 antibodies and preparations
IL256295A (en)	2018-02-28	Anti-ntb-a antibodies and related compositions and methods
EP3519946A4 (de)	2020-03-11	Hardware-beschleuniger und verfahren für offload-operationen
EP3405190A4 (de)	2019-10-30	Verfahren zur auslösung einer immunreaktion
EP3356390A4 (de)	2019-08-28	Verfahren und zusammensetzungen für antikörperausweichende virusvektoren
EP3328377A4 (de)	2019-03-13	Zusammensetzungen und verfahren für immun-onkologie-therapien
EP3331571A4 (de)	2019-04-10	Zusammensetzungen und verfahren zur behandlung von virusinfektionen
MA41863A (fr)	2021-06-02	Compositions et procédés permettant de traiter une anémie
EP3126524A4 (de)	2017-09-20	Verbesserte zusammensetzungen und verfahren für molekularinversionsprobenassays
EP3503879A4 (de)	2020-04-29	Zusammensetzung und verfahren dafür
EP3448981A4 (de)	2019-11-27	Zusammensetzungen und verfahren zur durchführung von magnetschwebetrennungen
EP3307296A4 (de)	2019-01-16	Verfahren und zusammensetzungen zur behandlung von altersassoziierten leiden
MA46542A (fr)	2021-03-31	Procédés et compositions pour une immunothérapie par tusc2
EP3298151A4 (de)	2019-04-10	Verfahren und zusammensetzungen zur bestimmung des ph-wertes
EP3429690A4 (de)	2019-10-23	Verfahren zur modulation von keap1
EP3350338A4 (de)	2019-07-17	Verfahren und zusammensetzungen zur detektion von mykotoxinen
EP3600399A4 (de)	2021-03-24	Verfahren und zusammensetzungen zur impfung gegen malaria
EP3319930A4 (de)	2019-04-10	Verfahren und zusammensetzungen zur stabilisierung von proteinen